Arrowhead’s ARO-ANG3 an Orphan Drug in U.S. for cholesterol disorder

Arrowhead Pharmaceuticals (NASDAQ:ARWR) is up 1% after hours on the heels of Orphan Drug designation in the U.S. for RNAi therapeutic ARO-ANG3 for the potential treatment of homozygous familial hypercholesterolemia (HoFH), an inherited disorder characterized by excessive levels of “bad” cholesterol in the blood.

A Phase 1 study is in process.

https://seekingalpha.com/news/3478235-arrowheads-aro-ang3-orphan-drug-u-s-hofh-shares-1-percent-hours